{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:39Z","timestamp":1791725979566,"version":"4.3.4"},"reference-count":332,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000132","name":"National Academies of Sciences Engineering and Medicine Transportation Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.lfs.2021.119301","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T11:28:44Z","timestamp":1614943724000},"page":"119301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs"],"prefix":"10.1016","volume":"274","author":[{"given":"Aditi","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Kanchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119301_bb0005","series-title":"Global Tuberculosis Report","author":"World Health Organisation","year":"2020"},{"key":"10.1016\/j.lfs.2021.119301_bb0010","article-title":"Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study","volume":"367","author":"Becerra","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2021.119301_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1473-3099(03)00483-3","article-title":"The effect of drug resistance on the fitness of Mycobacterium tuberculosis","volume":"3","author":"Cohen","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1369-5274(99)00005-3","article-title":"The biological cost of antibiotic resistance","volume":"2","author":"Andersson","year":"1999","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.48.4.1289-1294.2004","article-title":"Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis","volume":"48","author":"Mariam","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective","volume":"46","author":"Gillespie","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0035","series-title":"UN Interagency Coordination Group (IACG) on Antimicrobial Resistance","author":"WHO","year":"2020"},{"key":"10.1016\/j.lfs.2021.119301_bb0040","series-title":"Drug-resistant infections: a threat to our economic future (Vol. 2): final report (English). HNP\/Agriculture Global","author":"Jonas","year":"2017"},{"key":"10.1016\/j.lfs.2021.119301_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0966-842X(98)01216-5","article-title":"Mechanisms of latency in Mycobacterium tuberculosis","volume":"6","author":"Parrish","year":"1998","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0050","article-title":"The ongoing challenge of latent tuberculosis","volume":"369","author":"Esmail","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.lfs.2021.119301_bb0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijmyco.2016.09.017","article-title":"Reactivation or reinfection in adult tuberculosis: is that the question?","volume":"5","author":"Cardona","year":"2016","journal-title":"Int. J. Mycobacteriology."},{"key":"10.1016\/j.lfs.2021.119301_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","author":"Houben","year":"2016","journal-title":"PLoS Med.13"},{"key":"10.1016\/j.lfs.2021.119301_bb0065","doi-asserted-by":"crossref","unstructured":"M.A. Behr, P.H. Edelstein, L. Ramakrishnan, Revisiting the timetable of tuberculosis, BMJ. 362 (2018). doi:https:\/\/doi.org\/10.1136\/bmj.k2738.","DOI":"10.1136\/bmj.k2738"},{"key":"10.1016\/j.lfs.2021.119301_bb0070","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/resp.12067","article-title":"Challenges to the global control of tuberculosis","volume":"18","author":"Chiang","year":"2013","journal-title":"Respirology"},{"key":"10.1016\/j.lfs.2021.119301_bb0075","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkx506","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care","volume":"73","author":"Dookie","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/138955707782331740","article-title":"Overview of Anti-tuberculosis (TB) drugs and their resistance mechanisms","volume":"7","author":"Shi","year":"2007","journal-title":"Mini-Reviews Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0085","series-title":"First-and-second-line-drugs-and-drug-resistance @ dx.doi.org","first-page":"163","author":"Jnawali","year":"2013"},{"key":"10.1016\/j.lfs.2021.119301_bb0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycoacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119301_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3201\/\/EID1903.120246","article-title":"Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa","volume":"19","author":"Klopper","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.lfs.2021.119301_bb0105","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1086\/317598","article-title":"Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands","volume":"182","author":"Schwartz","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0110","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"50","author":"Hazb\u00f3n","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0115","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1128\/AAC.47.4.1241-1250.2003","article-title":"Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis","volume":"47","author":"Ramaswamy","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb0125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/AAC.50.3.1075-1078.2006","article-title":"Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA","volume":"50","author":"Leung","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber. Lung Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1993","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb0140","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1128\/jcm.35.3.719-723.1997","article-title":"Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level","volume":"35","author":"Telenti","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev.bi.65.070196.001243","article-title":"Molecular mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"65","author":"Blanchard","year":"1996","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.lfs.2021.119301_bb0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119301_bb0155","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","article-title":"Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations","volume":"40","author":"Moghazeh","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1590\/0074-02760150100","article-title":"Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil","volume":"110","author":"Prim","year":"2015","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"10.1016\/j.lfs.2021.119301_bb0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/JCM.05171-11","article-title":"Molecular characteristics of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam","volume":"50","author":"Minh","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1906-3","article-title":"Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa","volume":"16","author":"Dookie","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0175","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkq102","article-title":"rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China","author":"Chen","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijmyco.2014.06.004","article-title":"Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan","volume":"3","author":"Qazi","year":"2014","journal-title":"Int. J. Mycobacteriology."},{"key":"10.1016\/j.lfs.2021.119301_bb0185","first-page":"843","article-title":"Novel mutation detection IN rpoB OF rifampicin-resistant Mycobacterium tuberculosis using pyrosequencing","volume":"45","author":"Htike","year":"2014","journal-title":"Southeast Asian J. Trop. Med. Public Health."},{"key":"10.1016\/j.lfs.2021.119301_bb0190","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jiph.2015.05.003","article-title":"Molecular analysis of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis isolates by multiple allele specific polymerase chain reaction in Puducherry, South India","volume":"8","author":"Thirumurugan","year":"2015","journal-title":"J. Infect. Public Health."},{"key":"10.1016\/j.lfs.2021.119301_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-479","article-title":"Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa","volume":"14","author":"Bhembe","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2019.00819","article-title":"Uncovering the resistance mechanism of Mycobacterium tuberculosis to rifampicin due to RNA polymerase H451D\/Y\/R mutations from computational perspective","volume":"7","author":"Zhang","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng.1038","article-title":"Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes","volume":"44","author":"Comas","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119301_bb0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2958.2012.08099.x","article-title":"Fitness-compensatory mutations in rifampicin-resistant RNA polymerase","volume":"85","author":"Brandis","year":"2012","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0215","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dkt224","article-title":"Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates","volume":"68","author":"Brandis","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/AAC.01541-12","article-title":"Putative compensatory mutations in the rpoc gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission","volume":"57","author":"De Vos","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0225","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-5-62","article-title":"A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: A systemic review and meta-analysis","volume":"5","author":"Morgan","year":"2005","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1472-765X.2008.02403.x","article-title":"Molecular identification and characterization of rifampicin-resistant Mycobacterium tuberculosis isolates by line probe assay: An approach for rapid diagnosis of multidrug-resistant tuberculosis","volume":"47","author":"Bicmen","year":"2008","journal-title":"Lett. Appl. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0235","unstructured":"Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/10815743\/ (accessed September 4, 2020)."},{"key":"10.1016\/j.lfs.2021.119301_bb0240","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4236\/jtr.2016.44019","article-title":"High resolution melting curve analysis for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates","volume":"04","author":"Osman","year":"2016","journal-title":"J. Tuberc. Res."},{"key":"10.1016\/j.lfs.2021.119301_bb0250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis","volume":"41","author":"Scorpio","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0255","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.00110-08","article-title":"Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis","volume":"52","author":"Jur\u00e9en","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0260","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/bj3530453","article-title":"Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis","volume":"353","author":"Lemaitre","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2021.119301_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2011.09.010","article-title":"Molecular characterization of drug-resistant and -susceptible Mycobacterium tuberculosis isolated from patients with tuberculosis in Korea","volume":"72","author":"Yoon","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0270","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.61","article-title":"Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis","volume":"3","author":"Shi","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.lfs.2021.119301_bb0280","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0597-567","article-title":"The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol","volume":"3","author":"Telenti","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0285","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2008.10.017","article-title":"Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India","volume":"33","author":"Jadaun","year":"2009","journal-title":"Int. J. Antimicrobial Agents"},{"key":"10.1016\/j.lfs.2021.119301_bb0290","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/ng.2743","article-title":"Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-\u03b2-D-arabinose biosynthetic and utilization pathway genes","volume":"45","author":"Safi","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119301_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2018.00114","article-title":"Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains","volume":"8","author":"Hameed","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/JCM.01476-09","article-title":"Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis","volume":"48","author":"Via","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0305","first-page":"1032","article-title":"Molecular characterisation of streptomycin-resistant Mycobacterium tuberculosis strains isolated in Poland","volume":"8","author":"Brzostek","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1099\/jmm.0.05343-0","article-title":"Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico","volume":"53","author":"Ramaswamy","year":"2004","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0315","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.resmic.2004.06.007","article-title":"Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis","volume":"155","author":"Tracevska","year":"2004","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0320","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1365-2958.2006.05585.x","article-title":"Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria","volume":"63","author":"Okamoto","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4046\/trd.2017.80.2.159","article-title":"Mutations in streptomycin resistance genes and their relationship to streptomycin resistance and lineage of Mycobacterium tuberculosis Thai isolates","volume":"80","author":"Hlaing","year":"2017","journal-title":"Tuberc. Respir. Dis. (Seoul)"},{"key":"10.1016\/j.lfs.2021.119301_bb0330","first-page":"369","article-title":"Review article: review article","volume":"11","author":"Kilmer","year":"2010","journal-title":"Journal. Theory, Pract. Crit."},{"key":"10.1016\/j.lfs.2021.119301_bb0335","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.40.8.1768","article-title":"Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra","volume":"40","author":"Kocag\u00f6z","year":"1996","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"10.1016\/j.lfs.2021.119301_bb0340","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/07391102.2016.1277784","article-title":"Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis","volume":"36","author":"Pandey","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2021.119301_bb0345","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1128\/AAC.06272-11","article-title":"Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis","volume":"56","author":"Pantel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0350","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","article-title":"Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin","volume":"62","author":"Nosova","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0355","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000109769","article-title":"Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid","volume":"53","author":"Escribano","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lfs.2021.119301_bb0360","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1365-2958.2012.08168.x","article-title":"Capreomycin susceptibility is increased by TlyA-directed 2\u2032-O-methylation on both ribosomal subunits","volume":"85","author":"Monshupanee","year":"2012","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0365","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","article-title":"Capreomycin binds across the ribosomal subunit Interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs","volume":"23","author":"Johansen","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2021.119301_bb0370","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nsmb.1755","article-title":"The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome","volume":"17","author":"Stanley","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb0375","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/JCM.00201-10","article-title":"Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis","volume":"48","author":"Kiet","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033275","article-title":"Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: A systematic review","volume":"7","author":"Georghiou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb0385","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkr109","article-title":"Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis","volume":"66","author":"Engstr\u00f6m","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0390","doi-asserted-by":"crossref","first-page":"28326","DOI":"10.1074\/jbc.M003744200","article-title":"Activation of the pro-drug ethionamide is regulated in mycobacteria","volume":"275","author":"Baulard","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0395","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1128\/AAC.01030-10","article-title":"Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis","volume":"55","author":"Brossier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0400","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1128\/AAC.00647-15","article-title":"Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance","volume":"59","author":"Minato","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0405","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.01197-08","article-title":"Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis","volume":"53","author":"Mathys","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0410","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1128\/AAC.01775-13","article-title":"Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0415","first-page":"1","article-title":"Cycloserin","volume":"88","author":"Early","year":"2007","journal-title":"XPharm Compr. Pharmacol. Ref."},{"key":"10.1016\/j.lfs.2021.119301_bb0420","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/jac\/dkx316","article-title":"Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis","volume":"72","author":"Chen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0425","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.3548","article-title":"Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in d-cycloserine resistance","volume":"48","author":"Desjardins","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119301_bb0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1060028013504087","article-title":"Bedaquiline: A novel diarylquinoline for multidrug-resistant tuberculosis","volume":"48","author":"Chahine","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lfs.2021.119301_bb0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt0205-187","article-title":"Shortening the treatment of tuberculosis","volume":"23","author":"Mitchison","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119301_bb0440","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","volume":"57","author":"Diacon","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0445","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb0450","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0455","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023575","article-title":"Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase","volume":"6","author":"Haagsma","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2021.119301_bb0470","first-page":"811","article-title":"New drugs for the treatment of tuberculosis","volume":"40","author":"Ignatius","year":"2019","journal-title":"New Drugs Pharmacology"},{"key":"10.1016\/j.lfs.2021.119301_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics8040261","article-title":"Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline","volume":"8","author":"Sarathy","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.lfs.2021.119301_bb0480","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02383-2019","article-title":"Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients","volume":"55","author":"Nimmo","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb0485","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01719-2016","article-title":"Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: Lessons to avoid repeating past errors","volume":"49","author":"Veziris","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline","volume":"9","author":"Andries","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb0495","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: Its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0500","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/jac\/dkx094","article-title":"Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region","volume":"72","author":"Zimenkov","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0505","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1128\/AAC.00753-16","article-title":"Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis","volume":"60","author":"Almeida","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0510","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00239-17","article-title":"Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis","volume":"61","author":"Xu","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0515","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00142914","article-title":"A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment","volume":"45","author":"Somoskovi","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb0520","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0525","doi-asserted-by":"crossref","unstructured":"H. Ghajavand, M.K. Kamakoli, S. Khanipour, et al., High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness, Antimicrob. Agents Chemother. 63 (2019). doi:https:\/\/doi.org\/10.1128\/AAC.02530-18.","DOI":"10.1128\/AAC.02530-18"},{"key":"10.1016\/j.lfs.2021.119301_bb0530","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/AAC.01462-13","article-title":"Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis","volume":"58","author":"Gupta","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0535","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","article-title":"Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea","volume":"38","author":"Yang","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0540","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0545","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.lfs.2021.119301_bb0550","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0555","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0560","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(19)30363-7","article-title":"Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?","volume":"7","author":"McKenna","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0565","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119301_bb0570","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S2213-2600(19)30376-5","article-title":"Breakthrough in the treatment of drug-resistant tuberculosis","volume":"7","author":"Mushtaq","year":"2019","journal-title":"Lancet Respiratory Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0575","unstructured":"S. Scott, Tuberculosis treatment breakthrough could dramatically speed up cure, Researchers Say, (2014)."},{"key":"10.1016\/j.lfs.2021.119301_bb0580","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.lfs.2021.119301_bb0585","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1517\/13543784.2012.724397","article-title":"Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment","volume":"21","author":"Engohang-Ndong","year":"2012","journal-title":"Expert Opinion Investigational Drugs"},{"key":"10.1016\/j.lfs.2021.119301_bb0590","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00375-18","article-title":"Coenzyme F420-dependent glucose-6-phosphate dehydrogenase-coupled polyglutamylation of coenzyme F420 in mycobacteria","volume":"200","author":"Purwantini","year":"2018","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.lfs.2021.119301_bb0595","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","article-title":"Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0600","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1248\/bpb.b14-00311","article-title":"Delamanid does not inhibit or induce cytochrome P450 enzymes in vitro","volume":"37","author":"Shimokawa","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.lfs.2021.119301_bb0605","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","author":"Bloemberg","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0610","series-title":"Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis","author":"Rifat","year":"2018"},{"key":"10.1016\/j.lfs.2021.119301_bb0615","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone antibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.lfs.2021.119301_bb0620","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"10.1016\/j.lfs.2021.119301_bb0625","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.01189-07","article-title":"In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants [4]","volume":"52","author":"Hillemann","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0630","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/jac\/dkz150","article-title":"Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS","volume":"74","author":"Pi","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0635","doi-asserted-by":"crossref","unstructured":"R. Mirnejad, A. Asadi, S. Khoshnood, et al., Clofazimine: A useful antibiotic for drug-resistant tuberculosis, Biomed. Pharmacother. 105 (2018) 1353\u20131359. doi:https:\/\/doi.org\/10.1016\/j.biopha.2018.06.023.","DOI":"10.1016\/j.biopha.2018.06.023"},{"key":"10.1016\/j.lfs.2021.119301_bb0640","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/jac\/dkv150","article-title":"Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis","volume":"70","author":"Zhang","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0645","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.40.9.2137","article-title":"Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients","volume":"40","author":"Baohong","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0650","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1128\/AAC.32.12.1758","article-title":"In vitro and in vivo activities of macrolides against Mycobacterium leprae","volume":"32","author":"Franzblau","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0655","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1568005023342263","article-title":"Natural and Acquired macrolide resistance in mycobacteria","volume":"2","author":"Doucet-Populaire","year":"2002","journal-title":"Curr. Drug Targets - Infect. Disord."},{"key":"10.1016\/j.lfs.2021.119301_bb0660","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.48.1.143-150.2004","article-title":"Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex","volume":"48","author":"Buri\u00e1nkov\u00e1","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s101560050011","article-title":"Mechanisms of bacterial resistance to macrolide antibiotics","volume":"5","author":"Nakajima","year":"1999","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0670","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/AAC.49.4.1447-1454.2005","article-title":"In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis","volume":"49","author":"Falzari","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0675","first-page":"1","article-title":"The mycobacterial membrane: A novel target space for anti-tubercular drugs","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0680","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2125.1996.tb00175.x","article-title":"Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma","volume":"41","author":"Watkins","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119301_bb0685","doi-asserted-by":"crossref","unstructured":"P. Nunn, J. Porter, P. Winstanley, Thiacetazone\u2014avoid like poison or use with care?, Trans. R. Soc. Trop. Med. Hyg. 87 (1993) 578\u2013582. doi:https:\/\/doi.org\/10.1016\/0035-9203(93)90096-9.","DOI":"10.1016\/0035-9203(93)90096-9"},{"key":"10.1016\/j.lfs.2021.119301_bb0690","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/00003495-199243050-00003","article-title":"Drug treatment of tuberculosis-1992","volume":"43","author":"Davidson","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2021.119301_bb0695","doi-asserted-by":"crossref","unstructured":"A. Alahari, X. Trivelli, Y. Gu\u00e9rardel, et al., Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria, PLoS One. 2 (2007) 1343. doi:https:\/\/doi.org\/10.1371\/journal.pone.0001343.","DOI":"10.1371\/journal.pone.0001343"},{"key":"10.1016\/j.lfs.2021.119301_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053162","article-title":"Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues","volume":"8","author":"Coxon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb0705","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01063-06","article-title":"EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets","volume":"51","author":"Dover","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0710","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","article-title":"Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis","volume":"97","author":"DeBarber","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb0715","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/id500032q","article-title":"Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by isoxyl and thiacetazone","volume":"1","author":"Grzegorzewicz","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb0720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053162","article-title":"Synthesis, Antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues","volume":"8","author":"Coxon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb0725","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2958.2000.01882.x","article-title":"Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice","volume":"36","author":"Dubnau","year":"2000","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/S1097-2765(00)80250-6","article-title":"A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis","volume":"5","author":"Glickman","year":"2000","journal-title":"Mol. Cell."},{"key":"10.1016\/j.lfs.2021.119301_bb0735","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20041668","article-title":"Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule","author":"Rao","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0740","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/CMR.18.1.81-101.2005","article-title":"Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis","volume":"18","author":"Takayama","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2021.119301_bb0745","doi-asserted-by":"crossref","unstructured":"I. Halloum, A. Viljoen, V. Khanna, et al., Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB-4384, Antimicrob. Agents Chemother. 61 (2017). doi:https:\/\/doi.org\/10.1128\/AAC.02509-16.","DOI":"10.1128\/AAC.02509-16"},{"key":"10.1016\/j.lfs.2021.119301_bb0750","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0755","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis","volume":"56","author":"Tahlan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0760","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0765","doi-asserted-by":"crossref","unstructured":"P. Chen, J. Gearhart, M. Protopopova, et al., Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro, J. Antimicrob. Chemother. 58 (2006) 332\u2013337. doi:https:\/\/doi.org\/10.1093\/jac\/dkl227.","DOI":"10.1093\/jac\/dkl227"},{"key":"10.1016\/j.lfs.2021.119301_bb0770","doi-asserted-by":"crossref","unstructured":"N. Heinrich, R. Dawson, J. Bois, et al., Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients, J. Antimicrob. Chemother. 70 (2014) 1558\u20131566. doi:https:\/\/doi.org\/10.1093\/jac\/dku553.","DOI":"10.1093\/jac\/dku553"},{"key":"10.1016\/j.lfs.2021.119301_bb0775","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug","volume":"144","author":"Jia","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119301_bb0780","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcala","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0785","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","article-title":"Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions","volume":"41","author":"Shinabarger","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0790","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/AAC.00384-12","article-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis","volume":"56","author":"Williams","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0795","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0800","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.01182-08","article-title":"Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model","volume":"53","author":"Williams","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0805","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MCP.0000000000000045","article-title":"Tuberculosis: Clinical trials and new drug regimens","volume":"20","author":"Kwon","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0810","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2005.01.021","article-title":"Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages","volume":"25","author":"Sood","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119301_bb0815","unstructured":"M.J. Vjecha, S. Tiberi, A. Zumla, Title: Accelerating development and evaluation of new drugs and combination regimens for drug-resistant tuberculosis, (2018) 1\u201315."},{"key":"10.1016\/j.lfs.2021.119301_bb0820","unstructured":"L. Guijarro, J. Rullas, X. Li, et al., In vivo antitubercular activity of GSK070 , a Mycobacterium tuberculosis leucyl-tRNA synthetase inhibitor, (n.d.) 16005."},{"key":"10.1016\/j.lfs.2021.119301_bb0825","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nm.1950","article-title":"Synthetic EthR inhibitors boost antituberculous activity of ethionamide","volume":"15","author":"Willand","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0830","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/jm200825u","article-title":"Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors","volume":"55","author":"Flipo","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0835","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1016\/j.bmcl.2011.07.015","article-title":"Identification of SQ609 as a lead compound from a library of dipiperdines","volume":"21","author":"Bogatcheva","year":"2011","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bmcl.2009.10.135","article-title":"Discovery of dipiperidines as new antitubercular agents","volume":"20","author":"Bogatcheva","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb0845","article-title":"Studies on novel bacterial translocase I inhibitors, A-500359s","volume":"56","author":"Muramatsu","year":"2003","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.lfs.2021.119301_bb0850","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jac\/dkh417","article-title":"Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo","volume":"54","author":"Koga","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0855","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/AAC.00366-09","article-title":"Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis","volume":"53","author":"Nikonenko","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0860","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/dkq495","article-title":"Chemical modification of capuramycins to enhance antibacterial activity","volume":"66","author":"Bogatcheva","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0865","doi-asserted-by":"crossref","first-page":"30309","DOI":"10.1074\/jbc.M113.492173","article-title":"Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45","volume":"288","author":"Ishizaki","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0870","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4155\/tde.13.62","article-title":"Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis","volume":"4","author":"Salomon","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.lfs.2021.119301_bb0875","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/AAC.01514-10","article-title":"Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0880","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1128\/AAC.00417-10","article-title":"Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone","volume":"55","author":"Sekiguchi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0885","doi-asserted-by":"crossref","DOI":"10.4155\/fmc.15.128","article-title":"The anti-tuberculosis agents under development and the challenges ahead","author":"Kumar","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0890","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2011","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb0895","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00395-15","article-title":"Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis","volume":"59","author":"Lechartier","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0900","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/ml5003458","article-title":"Syntheses and antituberculosis activity of 1,3-benzothiazinone sulfoxide and sulfone derived from BTZ043","volume":"6","author":"Tiwari","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb0905","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb0910","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bmcl.2016.11.084","article-title":"Recent advancements in the development of anti-tuberculosis drugs","volume":"27","author":"Chetty","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00840-18","article-title":"Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169)","volume":"62","author":"Lupien","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0920","doi-asserted-by":"crossref","unstructured":"V. Makarov, O.B. Riabova, A. Yuschenko, et al., Synthesis and antileprosy activity of some dialkyldithiocarbamates, J. Antimicrob. Chemother. 57 (2006) 1134\u20131138. doi:https:\/\/doi.org\/10.1093\/jac\/dkl095.","DOI":"10.1093\/jac\/dkl095"},{"key":"10.1016\/j.lfs.2021.119301_bb0925","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1021\/jm401382v","article-title":"Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo","volume":"56","author":"Shirude","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0930","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1128\/AAC.03233-14","article-title":"1,4-azaindole, A potential drug candidate for treatment of tuberculosis","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0935","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1021\/jm500571f","article-title":"Lead optimization of 1,4-azaindoles as antimycobacterial agents","volume":"57","author":"Shirude","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0940","doi-asserted-by":"crossref","DOI":"10.1186\/s13065-018-0441-2","article-title":"Decaprenyl-phosphoryl-ribose 2\u2032-epimerase (DprE1): Challenging target for antitubercular drug discovery","volume":"12","author":"Gawad","year":"2018","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.lfs.2021.119301_bb0945","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00253-012-4013-4","article-title":"Antituberculars which target decaprenylphosphoryl-\u03b2-dribofuranose 2\u2032-oxidase DprE1: State of art","volume":"94","author":"Buroni","year":"2012","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119301_bb0950","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1007\/s00253-013-5218-x","article-title":"The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis","volume":"97","author":"Riccardi","year":"2013","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119301_bb0955","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/cb5007163","article-title":"2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1","volume":"10","author":"Neres","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb0960","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.bmc.2019.02.025","article-title":"Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline","volume":"27","author":"Blaser","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0965","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb0970","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1016\/j.bmcl.2017.10.042","article-title":"Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units","volume":"27","author":"Choi","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb0975","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01191-19","article-title":"TBAJ-876 retains bedaquiline\u2019s activity against subunits c and \u03b5 of Mycobacterium tuberculosis F-ATP synthase","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0980","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25061423","article-title":"Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876\u2014a less toxic and more potent analogue of bedaquiline","volume":"25","author":"Choi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119301_bb0985","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02404-19","article-title":"TBAJ-876, a 3,5-dialkoxypyridine analogue of bedaquiline, is active against Mycobacterium abscessus","volume":"64","author":"Sarathy","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0990","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01540-19","article-title":"TBAJ-876 displays bedaquiline-like mycobactericidal potency without retaining the parental drug\u2019s uncoupler activity","volume":"64","author":"Sarathy","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb0995","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1021\/jm5003606","article-title":"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent","volume":"57","author":"Kang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1000","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejmech.2016.09.082","article-title":"Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203","volume":"125","author":"Kang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1010","article-title":"The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd","volume":"8","author":"Lu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119301_bb1015","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.3390\/molecules19044380","article-title":"Synthesis and biological evaluation of novel 2-methoxypyridylamino- substituted riminophenazine derivatives as antituberculosis agents","volume":"19","author":"Zhang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119301_bb1020","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1021\/jm300828h","article-title":"Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis","volume":"55","author":"Zhang","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02155-18","article-title":"In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02496-18","article-title":"Identifying regimens containing TBI-166, a new drug candidate against Mycobacterium tuberculosis in vitro and in vivo","volume":"63","author":"Zhang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1035","series-title":"Investigating \u03b2-lactam drug targets in Mycobacterium tuberculosis using chemical probes","first-page":"2019","author":"Levine","year":"2019"},{"key":"10.1016\/j.lfs.2021.119301_bb1040","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/AAC.00320-06","article-title":"Crystal structure and activity studies of the Mycobacterium tuberculosis \u03b2-lactamase reveal its critical role in resistance to \u03b2-lactam antibiotics","volume":"50","author":"Wang","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1045","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/AAC.00665-12","article-title":"Inactivation of Mycobacterium tuberculosis L,D-transpeptidase Ldt Mt1 by carbapenems and cephalosporins","volume":"56","author":"Dub\u00e9e","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1050","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1128\/AAC.01663-13","article-title":"In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems","volume":"57","author":"Cordillot","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nchembio.2237","article-title":"Non-classical transpeptidases yield insight into new antibacterials","volume":"13","author":"Kumar","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb1060","article-title":"In vitro activity of \u03b2-lactams in combination with \u03b2-lactamase inhibitors against Mycobacterium tuberculosis clinical isolates","volume":"2018","author":"Li","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2021.119301_bb1065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234651","article-title":"Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges","volume":"15","author":"Chavan","year":"2020","journal-title":"PLoS One"},{"issue":"80","key":"10.1016\/j.lfs.2021.119301_bb1070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119301_bb1075","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0b013e3182154b05","article-title":"Meropenem\/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis","volume":"30","author":"Dauby","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1080","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1085","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","article-title":"Imipenem for treatment of tuberculosis in mice and humans","volume":"49","author":"Chambers","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1090","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/AAC.03539-14","article-title":"In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with \u03b2-lactamase inhibitors","volume":"58","author":"Horita","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1095","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1128\/AAC.01158-15","article-title":"Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus","volume":"59","author":"Kaushik","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1100","doi-asserted-by":"crossref","unstructured":"A. Kolloli, S. Subbian, Host-directed therapeutic strategies for tuberculosis, Front. Med. 4 (2017) 171. doi:https:\/\/doi.org\/10.3389\/fmed.2017.00171.","DOI":"10.3389\/fmed.2017.00171"},{"key":"10.1016\/j.lfs.2021.119301_bb1105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","article-title":"Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection","volume":"48","author":"Rodrigues-Junior","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119301_bb1110","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.00321-2015","article-title":"Mefloquine as a potential drug against multidrug-resistant tuberculosis","volume":"46","author":"Krieger","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1115","first-page":"1","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in vitro and in macrophages","volume":"2014","author":"Bermudez","year":"2014","journal-title":"Tuberc. Res. Treat."},{"key":"10.1016\/j.lfs.2021.119301_bb1120","series-title":"European Respiratory Society (ERS)","first-page":"PA3327","article-title":"Minimal inhibitory concentrations (MICs) of mefloquine: In vitro activity against MDR- and nonMDR-Tb strains","author":"Krieger","year":"2015"},{"key":"10.1016\/j.lfs.2021.119301_bb1125","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.1201538","article-title":"Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages","volume":"189","author":"Bruns","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119301_bb1130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","article-title":"Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis","volume":"10","author":"Napier","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2021.119301_bb1135","doi-asserted-by":"crossref","first-page":"35941","DOI":"10.1074\/jbc.M804543200","article-title":"Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components","volume":"283","author":"Yogalingam","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1004770","article-title":"Low doses of imatinib induce myelopoiesis and enhance host Anti-microbial immunity","volume":"11","author":"Napier","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119301_bb1145","doi-asserted-by":"crossref","unstructured":"R.S. Wallis, M. Maeurer, P. Mwaba, et al., Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers, Lancet Infect. Dis. 16 (2016) e34\u2013e46. doi:https:\/\/doi.org\/10.1016\/S1473-3099(16)00070-0.","DOI":"10.1016\/S1473-3099(16)00070-0"},{"key":"10.1016\/j.lfs.2021.119301_bb1150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2019.02.004","article-title":"Metformin as a host-directed therapeutic in tuberculosis: Is there a promise?","author":"Yew","year":"2019","journal-title":"Tuberculosis"},{"key":"10.1016\/j.lfs.2021.119301_bb1160","doi-asserted-by":"crossref","unstructured":"\u00c1. Mourenza, J.A. Gil, L.M. Mateos, Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing, (2020) 1\u201312.","DOI":"10.3390\/antibiotics9090550"},{"key":"10.1016\/j.lfs.2021.119301_bb1165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19095-z","article-title":"Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits","author":"B\u00f6hme","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2021.119301_bb1170","doi-asserted-by":"crossref","unstructured":"S. Tiberi, N. du Plessis, G. Walzl, et al., Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies, Lancet Infect. Dis. 18 (2018) e183\u2013e198. doi:https:\/\/doi.org\/10.1016\/S1473-3099(18)30110-5.","DOI":"10.1016\/S1473-3099(18)30110-5"},{"key":"10.1016\/j.lfs.2021.119301_bb1175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ebiom.2016.01.015","article-title":"Adjunctive phosphodiesterase- 4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model","volume":"4","author":"Subbian","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lfs.2021.119301_bb1180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajpath.2011.03.039","article-title":"Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology","volume":"179","author":"Subbian","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2021.119301_bb1185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002262","article-title":"Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid - mediated clearance of mycobacterium tuberculosis in rabbit lungs","volume":"7","author":"Subbian","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lfs.2021.119301_bb1190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017091","article-title":"Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice","volume":"6","author":"Koo","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2021.119301_bb1195","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijantimicag.2007.04.016","article-title":"Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice","volume":"30","author":"Dutta","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119301_bb1200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1472-765X.2008.02391.x","article-title":"The anti-inflammatory drug Diclofenac retains anti-listerial activity in vivo","volume":"47","author":"Dutta","year":"2008","journal-title":"Lett. Appl. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1205","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/bmj.1.6075.1500","article-title":"Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone","volume":"1","author":"Inman","year":"1977","journal-title":"Br. Med. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1210","doi-asserted-by":"crossref","first-page":"16004","DOI":"10.1073\/pnas.1214188109","article-title":"Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials","volume":"109","author":"Gold","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1215","doi-asserted-by":"crossref","first-page":"38915","DOI":"10.1074\/jbc.M206855200","article-title":"Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2","volume":"277","author":"Patel","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/AAC.00735-10","article-title":"Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor","volume":"55","author":"Kalle","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1225","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bmc.2015.03.041","article-title":"Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore","volume":"23","author":"Salunke","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1230","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","article-title":"Effects of low-dose aspirin on acute inflammatory responses in humans","volume":"183","author":"Morris","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119301_bb1235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/bmb\/ldw019","article-title":"Repurposing drugs for treatment of tuberculosis: A role for non-steroidal anti-inflammatory drugs","volume":"118","author":"Maitra","year":"2016","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.lfs.2021.119301_bb1245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2013-002672","article-title":"Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay","volume":"3","author":"Guzman","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.lfs.2021.119301_bb1250","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tips.2012.05.003","article-title":"NSAIDs: ENdocannabinoid stimulating anti-inflammatory drugs?","volume":"33","author":"Fowler","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2021.119301_bb1255","doi-asserted-by":"crossref","unstructured":"C. Vilaplana, E. Marzo, G. Tapia, et al., Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis, J. Infect. Dis. 208 (2013) 199\u2013202. doi:https:\/\/doi.org\/10.1093\/infdis\/jit152.","DOI":"10.1093\/infdis\/jit152"},{"key":"10.1016\/j.lfs.2021.119301_bb1260","first-page":"1925","volume":"208","author":"Eisen","year":"2013","journal-title":"Low-dose aspirin and ibuprofen\u2019s sterilizing effects on Mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis"},{"key":"10.1016\/j.lfs.2021.119301_bb1265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: Pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.lfs.2021.119301_bb1270","doi-asserted-by":"crossref","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis","author":"Young","year":"2020","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.lfs.2021.119301_bb1275","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9010021","article-title":"Host-directed therapy as a novel treatment strategy to overcome tuberculosis: Targeting immune modulation","author":"Ahmed","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.lfs.2021.119301_bb1280","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1016\/j.bmcl.2004.09.062","article-title":"Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic\/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide","volume":"14","author":"Cecchi","year":"2004","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb1285","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1183\/09031936.00113713","article-title":"Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis","volume":"43","author":"Alsaad","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1004917","article-title":"Neutrophil derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis","volume":"11","author":"Ong","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119301_bb1295","doi-asserted-by":"crossref","unstructured":"H. Salamon, N. Bruiners, K. Lakehal, et al., Cutting edge: Vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection, (2014). doi:https:\/\/doi.org\/10.4049\/jimmunol.1400736.","DOI":"10.4049\/jimmunol.1400736"},{"key":"10.1016\/j.lfs.2021.119301_bb1300","series-title":"Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis Is dependent on the induction of cathelicidin","volume":"179","author":"Liu","year":"2007"},{"key":"10.1016\/j.lfs.2021.119301_bb1305","article-title":"Convergence of IL-1 b and VDR activation pathways in human TLR2 \/ 1-induced antimicrobial responses","volume":"4","author":"Liu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb1310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003407","article-title":"Vitamin D induces interleukin-1\u03b2 expression: Paracrine macrophage epithelial signaling controls M. tuberculosis infection","volume":"9","author":"Verway","year":"2013","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.lfs.2021.119301_bb1315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-13-23","article-title":"Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: A dose finding study for treatment of tuberculosis","volume":"13","author":"Mily","year":"2013","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.chom.2009.08.004","article-title":"Vitamin D3 induces autophagy in human monocytes\/macrophages via cathelicidin","volume":"6","author":"Yuk","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2021.119301_bb1325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002689","article-title":"Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy","volume":"8","author":"Campbell","year":"2012","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.lfs.2021.119301_bb1330","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1073\/pnas.1200072109","article-title":"Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment","volume":"109","author":"Coussens","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2567.2008.03024.x","article-title":"1\u03b1,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection","volume":"127","author":"Coussens","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.lfs.2021.119301_bb1340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/sji.12006","article-title":"1,25-dihydroxyvitamin D3 inhibits nuclear factor kappa B activation by stabilizing inhibitor I\u03baB\u03b1 via mRNA stability and reduced phosphorylation in passively sensitized human airway smooth muscle cells","volume":"77","author":"Song","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.lfs.2021.119301_bb1345","doi-asserted-by":"crossref","unstructured":"M. Vidyarani, P. Selvaraj, M.S. Jawahar, et al., 1 , 25 Dihydroxyvitamin D 3 modulated cytokine response in pulmonary tuberculosis, Cytokine+. 40 (2007) 128\u2013134. doi:https:\/\/doi.org\/10.1016\/j.cyto.2007.08.005.","DOI":"10.1016\/j.cyto.2007.08.005"},{"key":"10.1016\/j.lfs.2021.119301_bb1350","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cyto.2012.06.238","article-title":"Effect of vitamin D 3 on chemokine expression in pulmonary tuberculosis","volume":"60","author":"Selvaraj","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.lfs.2021.119301_bb1355","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.intimp.2014.08.021","article-title":"1,25-Dihydroxy vitamin D3 downregulates pro-inflammatory cytokine response in pulmonary tuberculosis","volume":"23","author":"Harishankar","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2021.119301_bb1360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005007","article-title":"Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-Hydroxy-vitamin D\u2083","volume":"11","author":"Coussens","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119301_bb1365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-4-18","article-title":"Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials","volume":"4","author":"Edwards","year":"2003","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.lfs.2021.119301_bb1370","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/hq0801.094222","article-title":"In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products","volume":"21","author":"Diomede","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb1375","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0021-9150(02)00194-6","article-title":"Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells","volume":"165","author":"Ito","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lfs.2021.119301_bb1380","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb1385","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/jac\/dku166","article-title":"Simvastatin increases the in vivo activity of the first-line tuberculosis regimen","volume":"69","author":"Skerry","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1390","doi-asserted-by":"crossref","unstructured":"L.S. Lobato, P.S. Rosa, J. Da Silva Ferreira, et al., Statins increase rifampin Mycobactericidal effect, Antimicrob. Agents Chemother. 58 (2014) 5766\u20135774. doi:https:\/\/doi.org\/10.1128\/AAC.01826-13.","DOI":"10.1128\/AAC.01826-13"},{"key":"10.1016\/j.lfs.2021.119301_bb1395","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/IDR.S144446","article-title":"Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis","volume":"10","author":"Al-Saeedi","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.lfs.2021.119301_bb1400","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.39.12.2620","article-title":"Can penicillins and other \u03b2-lactam antibiotics be used to treat tuberculosis?","volume":"39","author":"Chambers","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119301_bb1405","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/bj1070675","article-title":"Properties of \u03b2-lactamases produced by three species of mycobacteria","volume":"107","author":"Kasik","year":"1968","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2021.119301_bb1410","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1126\/science.1094114","article-title":"The structure of a Mycobacterial outer-membrane channel","volume":"303","author":"Faller","year":"2004","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb1415","first-page":"4163","article-title":"Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis","volume":"48","author":"Stephan","year":"2004","journal-title":"Microbiology"},{"key":"10.1016\/j.lfs.2021.119301_bb1420","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1073\/pnas.96.7.4011","article-title":"A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates","volume":"96","author":"Liu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1425","series-title":"Requirement of the mymA Operon for Appropriate Cell Wall Ultrastructure and Persistence of Mycobacterium tuberculosis in the Spleens of Guinea Pigs","first-page":"4173","volume":"187","author":"Singh","year":"2005"},{"key":"10.1016\/j.lfs.2021.119301_bb1430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-1097(03)00648-7","article-title":"mymA operon of Mycobacterium tuberculosis: Its regulation and importance in the cell envelope","volume":"227","author":"Singh","year":"2003","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.lfs.2021.119301_bb1435","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00681","article-title":"New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria","volume":"8","author":"Nasiri","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1440","first-page":"1","article-title":"PE11, a PE\/PPE family protein of Mycobacterium tuberculosis is involved in cell wall remodeling and virulence","volume":"6","author":"Singh","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119301_bb1445","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nm.2120","article-title":"The Mycobacterium tuberculosis protein Ldt Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin","volume":"16","author":"Gupta","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1450","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"Para-aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis","volume":"288","author":"Zheng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1455","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1046\/j.1365-2958.1999.01310.x","article-title":"Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope","volume":"31","author":"Jackson","year":"1999","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1460","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00204-016-1727-6","article-title":"Antibiotic resistance mechanisms in Mtb: an update","volume":"90","author":"Nguyen","year":"2017","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.lfs.2021.119301_bb1465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bbrc.2014.05.090","article-title":"Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations","volume":"453","author":"Sun","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119301_bb1470","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevEukaryotGeneExpr.2014007826","article-title":"Comparative genomics of Mycobacterium tuberculosis drug efflux pumps and their transcriptional regulators","volume":"24","author":"Liu","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.lfs.2021.119301_bb1475","article-title":"Efflux pump mediated second-line tuberculosis drug resistance","volume":"6","author":"Malinga","year":"2016","journal-title":"Mycobact. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb1480","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","article-title":"Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism","volume":"145","author":"Adams","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119301_bb1485","first-page":"1","article-title":"Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb1490","doi-asserted-by":"crossref","unstructured":"J. Burian, S. Ram\u00f3n-Garc\u00eda, G. Sweet, et al., The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance, J. Biol. Chem. 287 (2012) 299\u2013310. doi:https:\/\/doi.org\/10.1074\/jbc.M111.302588.","DOI":"10.1074\/jbc.M111.302588"},{"key":"10.1016\/j.lfs.2021.119301_bb1495","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.0907925106","article-title":"Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis","volume":"106","author":"Zaunbrecher","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1500","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/jac\/dks497","article-title":"Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes","volume":"68","author":"Houghton","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"31","key":"10.1016\/j.lfs.2021.119301_bb1505","doi-asserted-by":"crossref","first-page":"E4523","DOI":"10.1073\/pnas.1606590113","article-title":"N -methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis","volume":"113","author":"Warrier","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.lfs.2021.119301_bb1510","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1515","first-page":"1","article-title":"Biochemical and structural characterization of Mycobacterium tuberculosis \u03b2-lactamase (BlaC) with the carbapenems ertapenem and doripenem","volume":"23","author":"Tremblay","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.lfs.2021.119301_bb1520","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1110699","article-title":"Biochemistry: a fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA","volume":"308","author":"Hegde","year":"2005","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2021.119301_bb1525","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1073\/pnas.1803313115","article-title":"Ribosome protection by antibiotic resistance ATP-binding cassette protein","volume":"115","author":"Su","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119301_bb1530","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tube.2003.08.003","article-title":"M. tuberculosis persistence, latency, and drug tolerance","volume":"84","author":"Gomez","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.lfs.2021.119301_bb1535","doi-asserted-by":"crossref","unstructured":"J. Burian, S. Ram\u00f3n-Garc\u00eda, G. Sweet, et al., The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance, J. Biol. Chem. 287 (2012) 299\u2013310. doi:https:\/\/doi.org\/10.1074\/jbc.M111.302588.","DOI":"10.1074\/jbc.M111.302588"},{"key":"10.1016\/j.lfs.2021.119301_bb1540","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1128\/JB.00879-12","article-title":"Interaction of CarD with RNA polymerase mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis","volume":"194","author":"Weiss","year":"2012","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.lfs.2021.119301_bb1545","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3201\/eid0907.020803","article-title":"Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family","volume":"9","author":"Ebrahimi-Rad","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb1550","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1582-4934.2003.tb00235.x","article-title":"QSAR - A piece of drug design","volume":"7","author":"P\u00e2rvu","year":"2003","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1555","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1381612822666151125000550","article-title":"Computer aided drug design: Success and limitations","volume":"22","author":"Hassan Baig","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2021.119301_bb1560","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1087057106296484","article-title":"A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase","volume":"12","author":"White","year":"2007","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.lfs.2021.119301_bb1565","doi-asserted-by":"crossref","unstructured":"Y. Jin, S. Fan, G. Lv, et al., Computer-aided drug design of capuramycin analogues as anti-tuberculosis antibiotics by 3D-QSAR and molecular docking, Open Chem. 15 (2017) 299\u2013307. doi:https:\/\/doi.org\/10.1515\/chem-2017-0039.","DOI":"10.1515\/chem-2017-0039"},{"key":"10.1016\/j.lfs.2021.119301_bb1570","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/156802610790232260","article-title":"3D-QSAR in drug design - a review","volume":"10","author":"Verma","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119301_bb1575","first-page":"1","article-title":"Mycobacterium tuberculosis H37Rv: in silico drug targets identification by metabolic pathways analysis ,Int","volume":"2014","author":"Amir","year":"2014","journal-title":"J. Evol. Biol."},{"key":"10.1016\/j.lfs.2021.119301_bb1580","first-page":"1","article-title":"Rational drug designing for drug target alanine racemase (Alr) of Mycobacterium tuberculosis","volume":"8","author":"Kushwaha","year":"2010","journal-title":"Internet J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119301_bb1585","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ddr.20413","article-title":"In silico subtractive genomics for target identification in human bacterial pathogens","volume":"72","author":"Barh","year":"2011","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.lfs.2021.119301_bb1590","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2017.11.014","article-title":"Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach","volume":"114","author":"Uddin","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119301_bb1595","first-page":"2011","article-title":"Generation and analysis of large-scale data-driven Mycobacterium tuberculosis functional networks for drug target identification","author":"Mazandu","year":"2011","journal-title":"Adv. Bioinforma."},{"key":"10.1016\/j.lfs.2021.119301_bb1600","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/bfgp\/elt012","article-title":"Functional genomics of intracellular bacteria","volume":"12","author":"De Barsy","year":"2013","journal-title":"Brief. Funct. Genomics."},{"key":"10.1016\/j.lfs.2021.119301_bb1605","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ijmm.2007.03.003","article-title":"Exploring functional genomics for the development of novel intervention strategies against tuberculosis","volume":"297","author":"Rachman","year":"2007","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1610","series-title":"An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis","author":"Furi\u00f3","year":"2020"},{"key":"10.1016\/j.lfs.2021.119301_bb1615","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-014-0263-5","article-title":"Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets","volume":"12","author":"Vashisht","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1620","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.smim.2014.09.013","article-title":"Systems-level modeling of mycobacterial metabolism for the identification of new (multi-)drug targets","volume":"26","author":"Rienksma","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2021.119301_bb1625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0205398","article-title":"High-resolution plasma metabolomics analysis to detect Mycobacterium tuberculosis associated metabolites that distinguish active pulmonary tuberculosis in humans","volume":"13","author":"Collins","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119301_bb1630","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.mib.2008.08.001","article-title":"Novel drug target strategies against Mycobacterium tuberculosis","volume":"11","author":"Murphy","year":"2008","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1635","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molmed.2010.10.004","article-title":"Novel targets in M. tuberculosis: search for new drugs","volume":"17","author":"Lamichhane","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2021.119301_bb1640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.02133-16","article-title":"Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis","volume":"8","author":"Dejesus","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.lfs.2021.119301_bb1645","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fmicb.2017.00465","article-title":"Tuberculosis hypothetical proteins and proteins of unknown function: hope for exploring novel resistance mechanisms as well as future target of drug resistance","volume":"8","author":"Sharma","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1650","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrmicro888","article-title":"Predicting the evolution of antibiotic resistance genes","volume":"2","author":"Hall","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2021.119301_bb1655","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.molcel.2018.10.015","article-title":"Inhibiting the evolution of antibiotic resistance","volume":"73","author":"Ragheb","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2021.119301_bb1660","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrmicro2133","article-title":"Drug interactions and the evolution of antibiotic resistance","volume":"7","author":"Yeh","year":"2009","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521002861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521002861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:48:27Z","timestamp":1758401307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521002861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":332,"alternative-id":["S0024320521002861"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119301","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119301"}}